For a few days it was suspiciously quiet at BioNTech, the last communication from the Mainz biotech company was dated September 17th – after that there was quiet. Today this calm has an end, BioNTech reports news on what is currently the most important vaccine project BNT162 – the vaccine against the pathogen of the rampant corona pandemic, the SARS-CoV-2 virus.
Together with development partner Pfizer, “the so-called” rolling review “submission process for the ongoing review of BNT162b2 at the European Medicines Agency (EMA) has been initiated”, reports BioNTech today. The basis is the data from previous clinical studies with the vaccine. “These indicate that vaccination with BNT162b2 triggers the production of neutralizing antibodies and leads to CD4 + and CD8 + T-cell responses, especially of the TH-1 type, against SARS-CoV-2,” said BioNTech. According to the company, these should “play an important role in protecting against viral infection and disease”.